Three-Drug Regimens Containing Integrase Inhibitor Show Good Efficacy and Safety in Treatment-Naive Patients With HIV-1: A Bayesian Analysis
Introduction: The extensive utilisation of antiretroviral therapy has greatly improved the survival rates of those infected with human immunodeficiency virus (HIV). The objective of this study was to compare 3-drug regimens containing non-nucleoside reverse transcriptase inhibitor with 3-drug regime...
Main Authors: | Ke Zhang, Yang Zhang, Xinchao Liu, Aixin Li, Meixia Gao, Jianhua Hou, Chunxiang Guo, Tong Zhang, Hao Wu, Guanzhi Chen, Xiaojie Huang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-07-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.603068/full |
Similar Items
-
Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens
by: Aleksey Viktorovich Kravchenko, et al.
Published: (2010-11-01) -
HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland
by: Parczewski Miłosz, et al.
Published: (2012-12-01) -
HIV-1 resistance patterns to integrase inhibitors in Chilean patients with virological failure on raltegravir-containing regimens
by: Pablo Ferrer, et al.
Published: (2020-09-01) -
The study of susceptibility and resistance of HIV integrases to integrase strand transfer inhibitors and the development of novel single domain antibody targeting HIV integrase
by: Ni, Xiaoju
Published: (2011) -
Integrase-RNA interactions underscore the critical role of integrase in HIV-1 virion morphogenesis
by: Jennifer L Elliott, et al.
Published: (2020-09-01)